SLC1A5 and hepatocellular carcinoma: The high-SLC1A5 patients had a greatly elevated TIDE score as opposed to that of the low-SLC1A5 patients in the TCGA HBV-related HCC cohort, indicating that a great trend towards immune escape was observed in the high-SLC1A5 patient group, which may fail to respond to ICB treatment (Figure 4D).